Boudoulas Konstantinos Dean, Pitsis Antonios, Triposkiadis Filippos, Han Yuchi, Savona Salvatore J, Stefanadis Christodoulos, Boudoulas Harisios
Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH, United States of America.
Thessaloniki Research Heart Institute, Thessaloniki, Greece.
Prog Cardiovasc Dis. 2022 Sep-Oct;74:89-98. doi: 10.1016/j.pcad.2022.10.010. Epub 2022 Oct 21.
It is well appreciated today that sudden cardiac death (SCD) occurs in patients with floppy mitral valve (FMV)/mitral valve prolapse (MVP) without significant mitral regurgitation . Data from studies most likely represent a heterogeneous population and probably underestimate the true incidence of SCD in this group of patients. SCD in patients with FMV/MVP occurs mostly in young individuals without comorbidities. Over the last decade, the phenotypic expression of patients with FMV/MVP at risk for SCD (bileaflet prolapse, redundant mitral leaflets, symptomatic young women) have been defined, possible pathophysiologic mechanisms leading to SCD have been proposed, and appropriate steps to prevent the catastrophic event, though in evolution, have been suggested. In this review, state-of-the-art knowledge related to SCD in patients with FMV/MVP is summarized.
如今人们已经充分认识到,心脏性猝死(SCD)会发生在患有二尖瓣脱垂(FMV)/二尖瓣脱垂(MVP)且无明显二尖瓣反流的患者中。研究数据很可能代表了一个异质性群体,并且可能低估了该组患者中SCD的真实发病率。FMV/MVP患者的SCD大多发生在无合并症的年轻个体中。在过去十年中,已明确了有SCD风险的FMV/MVP患者的表型表达(双叶脱垂、二尖瓣叶冗长、有症状的年轻女性),提出了导致SCD的可能病理生理机制,并且尽管仍在发展中,但已建议采取适当措施来预防这一灾难性事件。在这篇综述中,总结了与FMV/MVP患者SCD相关的最新知识。